An overview of adverse events reported by participants in CDC's Anthrax Vaccine and Antimicrobial Availability Program

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 6, 2005, Pages 393-401

  Martin, Stacey W ^a   Tierney, Bruce C ^a,c   Aranas, Aaron ^a   Rosenstein, Nancy E ^b   Franzke, Laura H ^a,d   Apicella, Louis ^a,e   Marano, Nina ^b   McNeil, Michael M ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d Logistics Health Incorporated   (United States)

^e POPULATION COUNCIL   (United States)

Author keywords

Adverse events; Anthrax vaccine; Antibiotics; Baccillus anthracis; Ciprofloxacin; Doxycycline; Post exposure prophylaxis; Surveillance

Indexed keywords

AMOXICILLIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; NEW DRUG; PENICILLIN G;

ADOLESCENT; ADULT; AGED; ANOREXIA; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTHROPATHY; BACILLUS ANTHRACIS; BLEEDING; CHEILITIS; CHILD; CHILL; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ERYTHEMA; FACE DISORDER; FACE EDEMA; FATIGUE; FEMALE; FOLLOW UP; GLOSSITIS; HALLUCINATION; HEADACHE; HEARTBURN; HUMAN; INFECTION PREVENTION; INJECTION PAIN; INJECTION SITE REACTION; INSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYCOSIS; NAUSEA; NIGHTMARE; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; PUBLIC HEALTH SERVICE; REVIEW; RIGOR; SEIZURE; SKIN BRUISING; SKIN BURNING SENSATION; SLEEP DISORDER; STOMACH PAIN; SYNCOPE; UNITED STATES; URTICARIA; VAGINITIS; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AMOXICILLIN; ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BIOTERRORISM; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHEMOPREVENTION; CIPROFLOXACIN; COHORT STUDIES; DATA COLLECTION; DOXYCYCLINE; FEMALE; FOLLOW-UP STUDIES; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; TIME FACTORS; UNITED STATES;

EID: 21244467081     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1085     Document Type: Review

References (19)

1. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 10: 1019-1028.
2. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002; 10: 1124-1132.
3. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. JAMA 1999; 281: 1735-1745.
4. CDC. Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49 (RR-15).
5. Tierney BC, Martin SW, Franzke LH, et al. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis 2003; 37: 905-911.
6. CDC Responds: Update on Options for Preventive Treatment for Persons at Risk for Inhalational Anthrax. December 21, 2001. Transcript located at: http://www.bt.cdc.gov/agent/anthrax/PreventiveTreatment12212001.asp
7. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956; 54: 28-36.
8. Friedlander AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167: 1239-1242.
9. Kournikakis B, Armour SJ, Boulet CA, Spence M, Barsons B. Risk assessment of anthrax threat letters. Suffield: DRES Technical Report TR 2001-04-8; September 2001.
10. CDC. Update: Adverse events associated with anthrax prophylaxis among postal employees - New Jersey, New York, and the District of Columbia Metropolitan Area. MMWR 2001; 50: 1051-1054.
11. Institute of Medicine. 2002. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL (eds). The Anthrax Vaccine: Is it safe? National Academy Press: Washington, DC.
12. In: Physicians desk reference. Available (to subscribers only) at http://www.pdrel.thomsonhc.com. [Accessed 5 December 2003].
13. Expedited safety reporting requirements for human drug and biological products. In Federal Register, Vol. 62. US Government Printing Office: Washington, DC, 1997.
14. MedDRA® is the international medical terminology developed under the auspices of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
15. Anthrax Vaccine Adsorbed (BIOTHRAX™) Package Insert. 2002. Manufactured by Bioport Corporation, Lansing Michigan, US Lic No. 1260.
16. Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, West DJ. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Safe 2002; 11: 189-202.
17. Jefferds MD, Roy S, Hayslett J, et al. Promoting postal workers' adherence to antibiotic prophylaxis to prevent inhalational anthrax - Washington, DC. In 51st Annual Epidemic Intelligence Service Conference Program and Abstracts Book. Centers for Disease Control and Prevention: Atlanta, 2002; 73.
18. Duffy LC, Zielezny MA, Marshall JR, et al. 1991. Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav Med 1991; 17: 101-110.
19. Lundberg U. Coping with stress: neuroendocrine reactions and implications for health. Noise Health 1999; 1: 67-74.